Prognostic Markers in Hospitalized COVID-19 Patients: The Role of IP-10 and C-Reactive Protein.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
11
2021
revised:
14
01
2022
accepted:
12
02
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
SARS-CoV-2 is responsible for COVID-19, a clinically heterogeneous disease, ranging from being completely asymptomatic to life-threating manifestations. An unmet clinical need is the identification at disease onset or during its course of reliable biomarkers allowing patients' stratification according to disease severity. In this observational prospective cohort study, patients' immunologic and laboratory signatures were analyzed to identify independent predictors of unfavorable (either death or intensive care unit admission need) or favorable (discharge and/or clinical resolution within the first 14 days of hospitalization) outcome. Between January and May 2021 (third wave of the pandemic), we enrolled 139 consecutive SARS-CoV-2 positive patients hospitalized in Northern Italy to study their immunological and laboratory signatures. Multiplex cytokine, chemokine, and growth factor analysis, along with routine laboratory tests, were performed at baseline and after 7 days of hospital stay. According to their baseline characteristics, the majority of our patients experienced a moderate to severe illness. At multivariate analysis, the only independent predictors of disease evolution were the serum concentrations of IP-10 (at baseline) and of C-reactive protein (CRP) after 7 days of hospitalization. Receiver-operating characteristic (ROC) curve analysis confirmed that baseline IP - 10 > 4271 pg/mL and CRP > 2.3 mg/dL at 7 days predict a worsening in clinical conditions (87% sensitivity, 66% specificity, area under the curve (AUC) 0.772, According to our results, baseline IP-10 and CRP after 7 days of hospitalization could be useful in driving clinical decisions tailored to the expected disease trajectory in hospitalized COVID-19 patients.
Sections du résumé
BACKGROUND
BACKGROUND
SARS-CoV-2 is responsible for COVID-19, a clinically heterogeneous disease, ranging from being completely asymptomatic to life-threating manifestations. An unmet clinical need is the identification at disease onset or during its course of reliable biomarkers allowing patients' stratification according to disease severity. In this observational prospective cohort study, patients' immunologic and laboratory signatures were analyzed to identify independent predictors of unfavorable (either death or intensive care unit admission need) or favorable (discharge and/or clinical resolution within the first 14 days of hospitalization) outcome.
METHODS
METHODS
Between January and May 2021 (third wave of the pandemic), we enrolled 139 consecutive SARS-CoV-2 positive patients hospitalized in Northern Italy to study their immunological and laboratory signatures. Multiplex cytokine, chemokine, and growth factor analysis, along with routine laboratory tests, were performed at baseline and after 7 days of hospital stay.
RESULTS
RESULTS
According to their baseline characteristics, the majority of our patients experienced a moderate to severe illness. At multivariate analysis, the only independent predictors of disease evolution were the serum concentrations of IP-10 (at baseline) and of C-reactive protein (CRP) after 7 days of hospitalization. Receiver-operating characteristic (ROC) curve analysis confirmed that baseline IP - 10 > 4271 pg/mL and CRP > 2.3 mg/dL at 7 days predict a worsening in clinical conditions (87% sensitivity, 66% specificity, area under the curve (AUC) 0.772,
CONCLUSIONS
CONCLUSIONS
According to our results, baseline IP-10 and CRP after 7 days of hospitalization could be useful in driving clinical decisions tailored to the expected disease trajectory in hospitalized COVID-19 patients.
Identifiants
pubmed: 35242241
doi: 10.1155/2022/3528312
pmc: PMC8886756
doi:
Substances chimiques
Biomarkers
0
CXCL10 protein, human
0
Chemokine CXCL10
0
Nerve Tissue Proteins
0
neuronal pentraxin
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3528312Informations de copyright
Copyright © 2022 Manuela Rizzi et al.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.
Références
Front Med (Lausanne). 2021 Oct 27;8:733274
pubmed: 34778296
Ann Med. 2021 Dec;53(1):1410-1418
pubmed: 34409900
Dis Markers. 2019 Jun 2;2019:4981982
pubmed: 31275447
Natl Sci Rev. 2020 Jun;7(6):1003-1011
pubmed: 34676126
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Sci Rep. 2020 Nov 26;10(1):20731
pubmed: 33244144
Front Immunol. 2020 Sep 02;11:2132
pubmed: 32983172
Front Immunol. 2021 Nov 10;12:745515
pubmed: 34858403
Dis Markers. 2021 May 13;2021:8863053
pubmed: 34055104
Int J Lab Hematol. 2021 Aug;43(4):O221-O223
pubmed: 33774907
Clin Chim Acta. 2020 Oct;509:91-94
pubmed: 32511972
Ann Clin Microbiol Antimicrob. 2020 May 15;19(1):18
pubmed: 32414383
Am J Infect Control. 2021 Jan;49(1):82-89
pubmed: 32540370
BMC Infect Dis. 2021 Jan 18;21(1):80
pubmed: 33461497
Int J Mol Sci. 2020 Nov 16;21(22):
pubmed: 33207699
Intern Emerg Med. 2021 Jun;16(4):1005-1015
pubmed: 33893976
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Sci Rep. 2021 Jul 5;11(1):13796
pubmed: 34226622
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Panminerva Med. 2021 Dec;63(4):478-481
pubmed: 32549532
Front Med (Lausanne). 2021 Apr 23;8:615333
pubmed: 33968948
J Med Virol. 2020 Jul;92(7):856-862
pubmed: 32281668
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Front Mol Biosci. 2021 Feb 22;8:632290
pubmed: 33693030
SAGE Open Med. 2021 Oct 11;9:20503121211050755
pubmed: 34659766
Clin Infect Dis. 2020 Nov 19;71(16):2174-2179
pubmed: 32445579
Cells. 2021 Jan 07;10(1):
pubmed: 33430260
Emerg Top Life Sci. 2020 Dec 11;4(4):371-378
pubmed: 33269805
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
Am J Emerg Med. 2021 Apr;42:60-69
pubmed: 33453617
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
Autoimmun Rev. 2014 Mar;13(3):272-80
pubmed: 24189283
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32427582
PLoS One. 2021 Jan 12;16(1):e0245296
pubmed: 33434221
Front Immunol. 2021 Aug 10;12:720363
pubmed: 34447386
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Reumatismo. 2021 Aug 03;73(2):117-121
pubmed: 34342213
Autoimmun Rev. 2013 Mar;12(5):554-7
pubmed: 23092582
Mol Med. 2020 Oct 29;26(1):97
pubmed: 33121429
Med Mal Infect. 2020 Jun;50(4):332-334
pubmed: 32243911
Int J Epidemiol. 2021 May 17;50(2):420-429
pubmed: 33683344
Crit Care. 2020 Jun 19;24(1):365
pubmed: 32560665
Ann Acad Med Singap. 2021 Nov;50(11):856-858
pubmed: 34877590
Immun Inflamm Dis. 2022 Mar;10(3):e582
pubmed: 34939346
Int J Infect Dis. 2020 Jun;95:304-307
pubmed: 32344011
Infect Dis (Lond). 2020 Oct;52(10):698-704
pubmed: 32584161
Minerva Med. 2020 Aug;111(4):303-305
pubmed: 33032392
Cancers (Basel). 2020 Jul 08;12(7):
pubmed: 32650523
Front Cardiovasc Med. 2020 Oct 09;7:585866
pubmed: 33195473
Reumatismo. 2020 Apr 10;72(1):16-20
pubmed: 32292017
Sci Rep. 2021 Oct 21;11(1):20793
pubmed: 34675240
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Cytokine Growth Factor Rev. 2020 Jun;53:25-32
pubmed: 32446778
Arch Virol. 2021 Dec;166(12):3301-3310
pubmed: 34554303
Curr Probl Cardiol. 2021 Mar;46(3):100742
pubmed: 33243440
BMJ. 2021 Dec 1;375:e065312
pubmed: 34853080
J Med Virol. 2021 Apr;93(4):2513-2522
pubmed: 33448439
Annu Rev Immunol. 2007;25:443-72
pubmed: 17243893
Front Immunol. 2020 Jul 10;11:1648
pubmed: 32754159
Rev Med Virol. 2021 Nov;31(6):e2221
pubmed: 34773448
Ann Intern Med. 2021 Jan;174(1):69-79
pubmed: 32941052